Health Catalyst (HCAT) shares fall 25.43% premarket after significant full-year guidance cut

Health Catalyst (HCAT) shares fell 25.43% in premarket trading on August 7, 2026, following a significant cut to full-year 2026 guidance released after Q2 earnings on August 6. The company lowered its revenue midpoint to $247.5 million and EBITDA to $18.25 million, citing the divestiture of Vitalware and operational headwinds, including a 28.1% drop in billings. The premarket decline represents a continuation of the sharp after-hours sell-off triggered by the earnings report.